<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151378">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941589</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-13-0401-OH-CTIL</org_study_id>
    <nct_id>NCT01941589</nct_id>
  </id_info>
  <brief_title>Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Ulcerative Colitis.</brief_title>
  <official_title>Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The role of steroids in the treatment of ulcerative Colitis (UC) is well established, and
      recommended by professional societies. However, there are no data investigating whether the
      addition and/or continuation of 5-aminosalicylic agents as combination therapy with systemic
      corticosteroids is superior to corticosteroids alone in patients with moderate-severe active
      UC. Thus, in practical terms, the decision regarding 5-aminosalicylic (to add or continue),
      on top of steroids treatment, is taken on an arbitrary basis. The aim of this study is to
      compare the efficacy of steroids alone Vs combination of steroids + 5-aminosalicylic in the
      treatment of moderate-severe UC exacerbation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">February 2015</completion_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>percentage of patients who respond to the treatment</measure>
    <time_frame>day 7</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>the percentage of patients in need of a rescue medication</measure>
    <time_frame>day 5, 7</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>colectomy rate</measure>
    <time_frame>1 month, 3 months post randomization</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>duration of hospitalization</measure>
    <time_frame>3-90</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>present 5-aminosalicylic acids+steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>present 5-aminosalicylic takers: maximal 5-aminosalicylic acid by mesalamine/ mesalazine 4 g/day + topical 5-aminosalicylic acid by 1 g/day enema (or suppository if not tolerated) + IV Hydrocortisone 100 mg *3/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stop present 5-aminosalicylic acids, take steroids only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>present 5-aminosalicylic takers: stop 5-aminosalicylic, take only IV Hydrocortisone 100 mg *3/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-aminosalicylic acids+steroids</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>none 5-aminosalicylic takers: maximal 5-aminosalicylic by mesalamine/mesalazine 4 g/day + topical 5-aminosalicylic by 1 g enema/ suppository + IV Hydrocortisone 100 mg *3/day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>none 5-aminosalicylic takers: steroids only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>none 5-aminosalicylic takers: IV Hydrocortisone 100 mg *3/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combination 5-aminosalicylic + hydrocortisone / prednisone</intervention_name>
    <description>combination 5-aminosalicylic + hydrocortisone / prednisone</description>
    <arm_group_label>present 5-aminosalicylic acids+steroids</arm_group_label>
    <arm_group_label>5-aminosalicylic acids+steroids</arm_group_label>
    <other_name>rafassal</other_name>
    <other_name>pentasa</other_name>
    <other_name>asacol</other_name>
    <other_name>hydrocortisone</other_name>
    <other_name>solu-cortef</other_name>
    <other_name>prednisone</other_name>
    <other_name>prenitone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV hydrocortisone / PO prednisone</intervention_name>
    <description>IV hydrocortisone / PO prednisone</description>
    <arm_group_label>stop present 5-aminosalicylic acids, take steroids only</arm_group_label>
    <arm_group_label>none 5-aminosalicylic takers: steroids only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ulcerative Colitis known for at least 3 months prior to admission

          -  current hospitalization with severe Ulcerative Colitis exacerbation

          -  age &gt;18

          -  hasn't been on oral systemic steroids 7 days prior to admission

          -  if taking thiopurines, the dose must be stable for 2 months prior to admission

        Exclusion Criteria:

          -  pregnant women

          -  allergy/unable to take study medications

          -  active infection

          -  severe renal/liver/cardiorespiratory condition

          -  toxic megacolon or signs of imminent colectomy

          -  treatment with an anti-tumor necrosis factor  in 3 months prior to admission

          -  prior treatment with cyclosporin or tacrolimus

          -  alcohol dependancy

          -  unwilling/ unable to give an informed consent

          -  participation in clinical trials in the last 2 months prior to admission
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ofir Har-Noy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center, Tel-Hashomer, ISRAEL 52621</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ofir Har-Noy, MD</last_name>
    <phone>+972-3-530-2679</phone>
    <email>ofirharnoy@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shomron Ben-Horin, MD</last_name>
    <phone>+972-3-530-2679</phone>
    <email>sben-horin@013net.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>tel-Hashomer, Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Ofir Har-Noy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer, Ramat-Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ofir Har-Noy, MD</last_name>
      <phone>+972-3-530-2679</phone>
      <email>ofirharnoy@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ofir Har-Noy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 25, 2013</lastchanged_date>
  <firstreceived_date>August 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Ofir Harnoy MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aminosalicylic Acid</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mesalamine</mesh_term>
    <mesh_term>Hydrocortisone-17-butyrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
